What we do Asston Pharmaceuticals Limited manufactures and markets generic pharmaceutical and nutraceutical products, focusing on tablets, capsules, syrups, sachets, and external preparations. |
Founded in 2,019 |
Market share Emerging player focusing on export markets with growing footprint in Asia and Africa. |
Problem solved Provides affordable generic and nutraceutical medicines to meet global and domestic health needs. |
Top clients or who we serve Exports to African and Asian countries; serves pharmaceutical distributors, hospitals, and retail pharmacies in B2B and B2C markets. |
Key management Ashish Narayan Sakalkar (MD), Saili Jayaram More (WTD & CEO), Rishabh Kumar Jain (Independent Director), Vijaya E Shahapurkar (Independent Director). |
Our journey and innovations Founded in 2019; acquired Ferron Lifecare in 2024 to enter nutraceuticals; achieved FDA approval same year; IPO held in 2025. |
Where we operate India-based with exports to Africa (multiple countries), Cambodia, and Vietnam. |
Top products or what we offer Generic tablets, capsules, oral liquids, nutraceutical syrups, sachets, and external topical preparations. |
Top brands - |
Raw materials needed Pharmaceutical chemicals and nutraceutical raw materials sourced from approved suppliers. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue driven by recurring pharmaceutical and nutraceutical product sales, with export cycle influences. |
Our industry position Growing company with significant export revenues; expanding FDA-approved production capacity. |
Financial highlights FY 2024-25 revenue Rs. 25.04 Crores with net profit Rs. 3.85 Crores; revenue growth ~57% year-over-year. |
Geographical revenue split Exports contribute 87% of revenue; domestic market 13%. |
Order book - |
Whats driving growth FDA approval, expanded nutraceutical portfolio, export market expansions, and successful IPO capital infusion. |
Our future plans Enhance production capacity, diversify product offerings, and expand international registrations and exports. |
Our green promise - |
Our people and values Experienced founders, commitment to quality, and fostering inclusive workplace adhering to regulatory standards. |
Key challenges ahead Maintaining compliance, expanding market access, managing supply chain and competitive pressures. |
Interesting facts FDA-approved facility producing up to 9 crore tablets monthly; successful IPO raised Rs. 27.56 crore in 2025. |
Risks and strategy Risks include regulatory approvals and market competition; mitigation via quality control, strategic expansions, and capital investment. |
